Harmol induces autophagy and subsequent apoptosis in U251MG human glioma cells through the downregulation of survivin

Abe,Akihisa; Kokuba,Hiroko

doi:10.3892/or.2013.2242

Harmol induces autophagy and subsequent apoptosis in U251MG human glioma cells through the downregulation of survivin

Authors:
- Akihisa Abe
- Hiroko Kokuba
View Affiliations

Affiliations: Department of Biochemistry, Tokyo Medical University, Shinjuku-ku, Tokyo 160-8402, Japan, Laboratory of Electron Microscopy, Tokyo Medical University, Shinjuku-ku, Tokyo 160-8402, Japan
Published online on: January 18, 2013 https://doi.org/10.3892/or.2013.2242
Pages: 1333-1342

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The β-carboline alkaloids are plant substances that exhibit a wide spectrum of neuropharmacological, psychopharmacological and antitumor effects. In the present study, we found that harmol, a β-carboline alkaloid, induced autophagy and suppression of survivin expression, and subsequently induced apoptotic cell death in U251MG human glioma cells. Autophagy was induced within 12 h by treatment with harmol. When treated for over 36 h, however, apoptotic cell death was induced. Harmol treatment also reduced survivin protein expression. Small interfering RNA (siRNA)-mediated knockdown of survivin enhanced the harmol-induced apoptosis. Knockdown of survivin by siRNA also induced autophagy. Therefore, harmol-induced apoptosis is a result of the reduction in survivin protein expression. Treatment with 3-methyladenine (3-MA) in the presence of harmol did not affect the expression of survivin and diminished harmol-induced cell death. Treatment with chloroquine in the presence of harmol did not suppress the reduction of survivin expression and increased harmol-induced cell death. From these results, harmol-induced reduction of survivin expression was closely related to autophagy. It is assumed that when isolation membrane formation is inhibited by treatment with 3-MA, reduction of survivin protein expression and apoptotic cell death were not induced. However, when isolation membrane formation is started and an autophagosome is formed, survivin expression is suppressed and apoptosis is executed. Harmol treatment reduced phosphorylation of Akt, mammalian target of rapamycin (mTOR) and its downstream targets p70-ribosomal protein S6 kinase and 4E-binding protein 1, resulting in induction of autophagy. Conversely, activation of the Akt/mTOR pathway inhibited harmol-induced autophagy and cell death. These findings indicate that harmol-induced autophagy involves the Akt/mTOR pathway. Taken together, autophagy induced by harmol represented a pro-apoptotic mechanism, and harmol suppressed the expression of survivin and subsequently induced apoptosis.

View Figures

View References

1	DeAngelis LM: Brain tumors. N Engl J Med. 344:114–123. 2001. View Article : Google Scholar : PubMed/NCBI
2	Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 9:157–173. 2006. View Article : Google Scholar : PubMed/NCBI
3	Kanzawa T, Kondo Y, Ito H, Kondo S and Germano I: Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 63:2103–2108. 2003.PubMed/NCBI
4	Fadeel B, Orrenius S and Zhivotovsky B: Apoptosis in human disease: a new skin for the old ceremony? Biochem Biophys Res Commun. 266:699–717. 1999. View Article : Google Scholar : PubMed/NCBI
5	Clarke PG: Developmental cell death: morphological diversity and multiple mechanisms. Anat Embryol. 181:195–213. 1990. View Article : Google Scholar : PubMed/NCBI
6	Brown JM and Attardi LD: The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 5:231–237. 2005.PubMed/NCBI
7	Klionsky DJ and Emr SD: Autophagy as a regulated pathway of cellular degradation. Science. 290:1717–1721. 2000. View Article : Google Scholar : PubMed/NCBI
8	Levine B and Klionsky DJ: Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 6:463–477. 2004. View Article : Google Scholar : PubMed/NCBI
9	Shintani T and Klionsky DJ: Autophagy in health and disease: a double-edged sword. Science. 306:990–995. 2004. View Article : Google Scholar : PubMed/NCBI
10	Gozuacik D and Kimchi A: Autophagy as a cell death and tumor suppressor mechanism. Oncogene. 23:2891–2906. 2004. View Article : Google Scholar : PubMed/NCBI
11	Debnath J, Baehrecke EH and Kroemer G: Does autophagy contribute to cell death? Autophagy. 1:66–74. 2005. View Article : Google Scholar : PubMed/NCBI
12	Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature. 451:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
13	Ogier-Denis E and Codogno P: Autophagy: a barrier or an adaptive response to cancer. Biochim Biophys Acta. 1603:113–128. 2003.PubMed/NCBI
14	Corcelle E, Nebout M, Bekri S, et al: Disruption of autophagy at the maturation step by the carcinogen lindane is associated with the sustained mitogen-activated protein kinase/extracellular signal-regulated kinase activity. Cancer Res. 66:6861–6870. 2006. View Article : Google Scholar
15	Otsuka H and Moscowitz M: Differences in the rates of protein degradation in untransformed and transformed cell lines. Exp Cell Res. 112:127–135. 1978. View Article : Google Scholar : PubMed/NCBI
16	Kirkegaad K, Taylor MP and Jacson WT: Cellular autophagy: surrender, avoidance and subversion by microorganisms. Nat Rev Microbiol. 2:301–314. 2004. View Article : Google Scholar : PubMed/NCBI
17	List PH and Hörhammer L: Hager’s Hand book for Pharmaceutical Practice. Springer-Verlag; Berlin: 1970
18	Naranjo C: Psychotropic properties of the harmala alkaloids. Ethnopharmacological Search for Psychoactive Drugs. Efron DH, Holmestedt B and Kline NS: U.S. Public Health Service; New York: pp. 385–392. 1967
19	Nadikarni KM: Indian Material Medica. 1. Popular Pakistan Limited; Bombay: pp. 927–929. 1976
20	Dymock W, Warden CJ and Hooper D: Pharmacopia Indica. 1. Harmad National Foundation of Pakistan; pp. 252–253. 1976
21	Khan SI, Abourashed EA, Khan IA and Walker LA: Transport of human alkaloids across Caco-2 cell monolayers. Chem Pharm Bull. 52:394–397. 2004. View Article : Google Scholar : PubMed/NCBI
22	Airaksinen MM and Kari I: β-carbolines, psychoactive compounds in the mammalian body. Part I: occurrence, origin and metabolism. Med Biol. 59:21–34. 1981.
23	Beck O and Faull KF: Concentrations of the enantiomers of 5-hydroxymethylptoline in mammalian urine: Implications for in vivo biosynthesis. Biochem Pharmacol. 65:97–106. 1986.PubMed/NCBI
24	Sobhani AM, Ebrahimi SA and Mahmoudian MJ: An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seed extract and its beta-carboline alkaloids. Pharm Pharm Sci. 5:19–23. 2002.PubMed/NCBI
25	Lamchouri F, Setaff A, Cherrah Y, et al: Antitumor principles from Peganum harmala seeds. Therapie. 54:753–758. 1999.PubMed/NCBI
26	Kuo PC, Shi LS, Damu AG, et al: Cytotoxic and antimalarial beta-carboline alkaloids from the roots of Eurycoma longifolia. J Nat Prod. 66:1324–1327. 2003. View Article : Google Scholar : PubMed/NCBI
27	Abe A and Yamada H: Harmol induces apoptosis by caspase-8 activation independently of Fas/Fas ligand interaction in human lung carcinoma H596 cells. Anticancer Drugs. 20:373–381. 2009. View Article : Google Scholar : PubMed/NCBI
28	Abe A, Yamada H, Moriya S and Miyazawa K: The β-carboline alkaloid harmol induces cell death via autophagy but not apoptosis in human non-small cell lung cancer A549 cells. Biol Pharm Bull. 34:1264–1272. 2011.
29	Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G and Murcia JM: Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem. 273:33533–33539. 1998. View Article : Google Scholar : PubMed/NCBI
30	Biederbick A, Kern HF and Elsässer HP: Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur J Cell Biol. 66:3–14. 1995.PubMed/NCBI
31	Kabeya Y, Mizusima N, Ueno T, et al: LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 19:5720–5728. 2000. View Article : Google Scholar : PubMed/NCBI
32	Seglen PO and Gordon PB: 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci USA. 79:1889–1892. 1982. View Article : Google Scholar : PubMed/NCBI
33	Kawai A, Uchiyama H, Takano S, Nakamura S and Ohkuma S: Autophagosome-lysosome fusion depends on the pH in acidic compartments in CHO cells. Autophagy. 3:154–157. 2007. View Article : Google Scholar : PubMed/NCBI
34	Rubinsztein DC, Gestwicki JE, Murphy LO and Klionsky DJ: Potential therapeutic applications of autophagy. Nat Rev Drug Discov. 6:304–312. 2007. View Article : Google Scholar : PubMed/NCBI
35	Fu L, Kim AY, Wang X, et al: Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res. 69:8967–8976. 2009. View Article : Google Scholar : PubMed/NCBI
36	Viola G, Bortolozzi R, Hamel E, et al: MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochem Pharmacol. 8:16–26. 2012. View Article : Google Scholar : PubMed/NCBI
37	Hung JY, Hsu YL, Li CT, et al: 6-Shogaol, an active constituent of dietary ginger, induces autophagy by inhibiting the AKT/mTOR pathway in human non-small cell lung cancer A549 cells. J Agric Food Chem. 57:9809–9816. 2009. View Article : Google Scholar : PubMed/NCBI
38	Takeuchi H, Kanzawa T, Kondo Y and Kondo S: Inhibition of platelet-derived growth factor signaling induces autophagy in malignant glioma cells. Br J Cancer. 90:1069–1075. 2004. View Article : Google Scholar : PubMed/NCBI
39	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
40	Gross A, Yin XM, Wang K, et al: Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem. 274:1156–1163. 1999. View Article : Google Scholar : PubMed/NCBI
41	Zha J, Weiler S, Oh KJ, Wei MC and Korsmeyer SJ: Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science. 290:1761–1765. 2000. View Article : Google Scholar : PubMed/NCBI
42	Shao RG, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E and Pommier Y: Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene. 20:1852–1859. 2001. View Article : Google Scholar : PubMed/NCBI
43	Deveraux Q and Reed JC: IAP family proteins: suppressors of apoptosis. Genes Dev. 13:239–252. 1999. View Article : Google Scholar : PubMed/NCBI
44	Li F, Ambrosini G, Chu EY, et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI
45	Monzo M, Rosell R, Felip E, et al: A novel anti-apoptosis gene: re-expression of surviving messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 17:2100–2104. 1999.PubMed/NCBI
46	Adida C, Haioun C, Gaulard P, et al: Prognostic significance of surviving expression in diffuse large B-cell lymphomas. Blood. 96:1921–1925. 2000.PubMed/NCBI
47	Kato J, Kuwabara Y, Mitani M, et al: Expression of surviving in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
48	Altieli DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar : PubMed/NCBI
49	Levine B and Yuan J: Autophagy in cell death: an innocent convict? J Clin Invest. 115:2679–2688. 2005. View Article : Google Scholar : PubMed/NCBI
50	Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar
51	Petiot A, Pattingre S, Arico S, Meley D and Codongo P: Diversity of signaling controls of macroautophagy in mammalian cells. Cell Struct Funct. 27:431–441. 2002. View Article : Google Scholar : PubMed/NCBI
52	Pattingre S, Bauvy C and Codongo P: Amino acids interfere with the ERK1/2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells. J Biol Chem. 278:16667–16674. 2003. View Article : Google Scholar : PubMed/NCBI
53	Meley D, Bauvy C, Houben-Weerts JH, et al: AMP-activated protein kinase and the regulation of autophagic proteolysis. J Biol Chem. 281:34870–34879. 2006. View Article : Google Scholar : PubMed/NCBI
54	Herrero-Martín G, Høyer-Hansen M, García-García C, et al: TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 28:677–685. 2009.PubMed/NCBI
55	Djavaheri-Mergny M, Maiuri MC and Kroemer G: Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene. 29:1717–1719. 2010. View Article : Google Scholar : PubMed/NCBI
56	Zhou F, Yang Y and Xing D: Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J. 278:403–413. 2011. View Article : Google Scholar : PubMed/NCBI
57	Lin CC, Lee CW, Chu TH, et al: Transactivation of Src, PDGF receptor, and Akt is involved in IL-1beta-induced ICAM-1 expression in A549 cells. J Cell Physiol. 211:771–780. 2007. View Article : Google Scholar : PubMed/NCBI
58	Russo P, Catassi A, Cesario A and Servent D: Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system. Curr Med Chem. 13:3493–3512. 2006. View Article : Google Scholar : PubMed/NCBI
59	Akca H, Tani M, Hishida T, Matsumoto S and Yokota J: Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer. 54:25–33. 2006. View Article : Google Scholar : PubMed/NCBI
60	Kishimoto H, Ohteki T, Yajima N, et al: The Pten/PI3K pathway governs the homeostasis of Valpha14iNKT cells. Blood. 109:3316–3324. 2007. View Article : Google Scholar : PubMed/NCBI
61	Takeuchi H, Kondo Y, Fujiwara K, et al: Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 65:3336–3346. 2005.PubMed/NCBI
62	Rommelspacher H, Nanz C, Borbe HO, Fehske KJ, Müller WE and Wollert U: 1-Methyl-beta-carboline (harmane), a potent endogenous inhibitor of benzodiazepine receptor binding. Naunyn Schmiedebergs Arch Pharmacol. 314:97–100. 1980. View Article : Google Scholar : PubMed/NCBI
63	Ho BT: Pharmacological and biochemical studies with beta-carboline analogs. Curr Dev Psychopharmacol. 4:151–177. 1977.PubMed/NCBI
64	Poirier LJ, Sourkes TL, Bouvier G, Boucher R and Carabin S: Striatal amines, experimental tremor and the effect of harmaline in the monkey. Brain. 89:37–52. 1966. View Article : Google Scholar : PubMed/NCBI
65	Bruinvels J and Sourkes TL: Influence of drugs on the temperature-lowering effect of harmaline. Eur J Pharmacol. 4:31–39. 1969. View Article : Google Scholar
66	Zetler G, Back G and Iven H: Pharmacokinetics in the rat of the hallucinogenic alkaloids harmine and harmaline. Naunyn Shemiedebergs Arch Pharmacol. 285:273–292. 1974. View Article : Google Scholar : PubMed/NCBI
67	Grella B, Dukat M, Young R, et al: Investigation of hallucinogenic and related beta-carbolines. Drug Alcohol Depend. 50:99–107. 1998. View Article : Google Scholar : PubMed/NCBI
68	Udenfriend S, Wiycop B, Redfield BG and Weissbach H: Studies with reversible inhibitors of monoamine oxidase: harmaline and related compounds. Biochem Pharmacol. 1:160–165. 1958. View Article : Google Scholar
69	McIsaac WM and Estevez V: Structure-action relationship of beta-carbolines as monoamine oxidase inhibitors. Biochem Pharmacol. 15:1625–1627. 1966. View Article : Google Scholar : PubMed/NCBI
70	Loew GH, Nienow J, Lawson JA, Toll L and Uyeno ET: Theoretical structure-activity studies of beta-carboline analogs. Requirements for benzodiazepine receptor affinity and antagonist activity. Mol Pharmacol. 28:17–31. 1985.
71	Kim H, Sablin SO and Ramsay RR: Inhibition of monoamine oxidase A by β-carboline derivatives. Arch Biochem Biophys. 337:137–142. 1997.
72	Gunn JA: Relations between chemical constitution, pharmacological actions, and therapeutic uses in the harmine group of alkaloids. Arch Int Pharmacodyn. 50:379–396. 1935.
73	Zetler G, Singbart G and Schlosser L: Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids. Pharmacology. 7:237–248. 1972. View Article : Google Scholar : PubMed/NCBI
74	Yu AM, Idle JR, Krausz KW, Küpfer A and Gonzalez FJ: Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther. 305:315–322. 2003. View Article : Google Scholar : PubMed/NCBI
75	Slotkin TA, DiStefano V and Au WY: Blood levels and urinary excretion of harmine and its metabolites in man and rats. J Pharmacol Exp Ther. 173:26–30. 1970.PubMed/NCBI